EUVIMEDEUVIMED entdecken
Crossref

Cyclic adenosine monophosphate critically modulates cardiac GLP-1 receptor’s anti-inflammatory effects

Renee A Stoicovy, Natalie Cora, Arianna Perez, Deepika Nagliya, Giselle Del Calvo, Teresa Baggio Lopez, Emma C Weinstein, Jordana I Borges, Jennifer Maning, Anastasios Lymperopoulos

Inflammation Research · 2024

DOI: 10.1007/s00011-024-01950-0 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Inflammation Research, 2024. Verfasst von Renee A Stoicovy und 9 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory for the Study of Neurohormonal Control of the Circulation, Department of Pharmaceutical Sciences (Pharmacology), Barry and Judy Silverman …. Hauptthemen laut MEDLINE: Glucagon-Like Peptide-1 Receptor, Cyclic AMP, Lipopolysaccharides, Liraglutide. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 56 Literaturangaben. Gefördert von: NHLBI NIH HHS, American Foundation for Pharmaceutical Education, National Heart, Lung, and Blood Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Glucagon-like peptide (GLP)-1 receptor (GLP1R) agonists exert a multitude of beneficial cardiovascular effects beyond control of blood glucose levels and obesity reduction. They also have anti-inflammatory actions through both central and peripheral mechanisms. GLP1R is a G protein-coupled receptor (GPCR), coupling to adenylyl cyclase (AC)-stimulatory Gs proteins to raise cyclic 3`-5`-adenosine monophosphate (cAMP) levels in cells. cAMP exerts various anti-apoptotic and anti-inflammatory effects via its effectors protein kinase A (PKA) and Exchange protein directly activated by cAMP (Epac). However, the precise role and importance of cAMP in mediating GLP1R`s anti-inflammatory actions, at least in the heart, remains to be determined. To this end, we tested the effects of the GLP1R agonist liraglutide on lipopolysaccharide (LPS)-induced acute inflammatory injury in H9c2 cardiac cells, either in the absence of cAMP production (AC inhibition) or upon enhancement of cAMP levels via phosphodiesterase (PDE)-4 inhibition with roflumilast. METHODS & RESULTS: Liraglutide dose-dependently inhibited LPS-induced apoptosis and increased cAMP levels in H9c2 cells, with roflumilast but also PDE8 inhibition further enhancing cAMP production by liraglutide. GLP1R-stimulated cAMP markedly suppressed the LPS-dependent induction of pro-inflammatory tumor necrosis factor (TNF)-a, interleukin (IL)-1b, and IL-6 cytokine expression, of inducible nitric oxide synthase (iNOS) expression and nuclear factor (NF)-kB activity, of matrix metalloproteinases (MMP)-2 and MMP-9 levels and activities, and of myocardial injury markers in H9c2 cardiac cells. The effects of liraglutide were mediated by the GLP1R since they were abolished by the GLP1R antagonist exendin(9-39). Importantly, AC inhibition completely abrogated liraglutide`s suppression of LPS-dependent inflammatory injury, whereas roflumilast significantly enhanced the protective effects of liraglutide against LPS-induced inflammation. Finally, PKA inhibition or Epac1/2 inhibition alone only partially blocked liraglutide`s suppression of LPS-induced inflammation in H9c2 cardiac cells, but, together, PKA and Epac1/2 inhibition fully prevented liraglutide from reducing LPS-dependent inflammation. CONCLUSIONS: cAMP, via activation of both PKA and Epac, is essential for GLP1R`s anti-inflammatory signaling in cardiac cells and that cAMP levels crucially regulate the anti-inflammatory efficacy of GLP1R agonists in the heart. Strategies that elevate cardiac cAMP levels, such as PDE4 inhibition, may potentiate the cardiovascular, including anti-inflammatory, benefits of GLP1R agonist drugs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glucagon-Like Peptide-1 ReceptorCyclic AMPLipopolysaccharidesLiraglutideAnti-Inflammatory AgentsGlucagon-Like Peptide-1 Receptor AgonistsAnimalsRatsCell LineMyocytes, CardiacNitric Oxide Synthase Type IICyclic AMP-Dependent Protein KinasesCytokinesAminopyridinesMatrix Metalloproteinase 2InflammationBenzamides

Stichwörter der Autor:innen

Cardiac myocyteCyclic adenosine monophosphateCytokinesGLP-1 receptorInflammationLiraglutideMatrix metalloproteinasePhosphodiesterase-4 inhibitorSignal transduction

Substanzen

Glucagon-Like Peptide-1 ReceptorCyclic AMPLipopolysaccharidesLiraglutideAnti-Inflammatory AgentsNitric Oxide Synthase Type IIGlp1r protein, ratCyclic AMP-Dependent Protein KinasesCytokinesAminopyridines

Autor:innen und Institutionen

  • Laboratory for the Study of Neurohormonal Control of the Circulation, Department of Pharmaceutical Sciences (Pharmacology), Barry and Judy Silverman College of Pharmacy, Nova Southeastern University, Fort Lauderdale, FL…
  • Northwestern University Feinberg School of Medicine, Chicago, IL, 60611, USA.
  • , University Dr., HPD (Terry) Bldg./Room 1350, Fort Lauderdale, FL, 33328-2018, USA. al806@nova.edu.

Förderung

  • NHLBI NIH HHS
  • American Foundation for Pharmaceutical Education
  • National Heart, Lung, and Blood Institute

Zitieren

APA

Stoicovy, R. A., Cora, N., Perez, A., Nagliya, D., Del Calvo, G., Lopez, T. B., Weinstein, E. C., Borges, J. I., Maning, J., & Lymperopoulos, A. (2024). Cyclic adenosine monophosphate critically modulates cardiac GLP-1 receptor’s anti-inflammatory effects. Inflammation Research. https://doi.org/10.1007/s00011-024-01950-0

Vancouver

Stoicovy RA, Cora N, Perez A, Nagliya D, Del Calvo G, Lopez TB, et al. Cyclic adenosine monophosphate critically modulates cardiac GLP-1 receptor’s anti-inflammatory effects. Inflammation Research. 2024. doi:10.1007/s00011-024-01950-0

BibTeX
@article{Stoicovy2024,
  author = {Stoicovy, Renee A and Cora, Natalie and Perez, Arianna and Nagliya, Deepika and Del Calvo, Giselle and Lopez, Teresa Baggio and Weinstein, Emma C and Borges, Jordana I and Maning, Jennifer and Lymperopoulos, Anastasios},
  title = {Cyclic adenosine monophosphate critically modulates cardiac GLP-1 receptor’s anti-inflammatory effects},
  journal = {Inflammation Research},
  year = {2024},
  doi = {10.1007/s00011-024-01950-0}
}
Kostenlos starten →